Larimar Therapeutics Files 8-K on Shareholder Vote Matters

TL;DR

Larimar (LRMR) filed an 8-K on shareholder votes. Keep an eye on the outcome.

AI Summary

Larimar Therapeutics, Inc. filed an 8-K on May 31, 2024, reporting on matters submitted to a vote of security holders as of May 29, 2024. The company, formerly known as Zafgen, Inc., is incorporated in Delaware and headquartered in Bala Cynwyd, Pennsylvania.

Why It Matters

This filing indicates important corporate actions or decisions that have been put before Larimar Therapeutics' shareholders for a vote, which could impact the company's future direction.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of matters submitted for a shareholder vote, not an announcement of significant financial or operational changes.

Key Numbers

• 001-36510 — SEC File Number (Identifies the company's filing history with the SEC.)
• 20-3857670 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Larimar Therapeutics, Inc. (company) — Registrant
• Zafgen, Inc. (company) — Former company name
• May 29, 2024 (date) — Date of earliest event reported
• May 31, 2024 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation
• Bala Cynwyd, Pennsylvania (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share LRMR Nasdaq Global Market

Filing Documents

• lrmr-20240529.htm (8-K) — 83KB
• 0000950170-24-067306.txt ( ) — 192KB
• lrmr-20240529.xsd (EX-101.SCH) — 23KB
• lrmr-20240529_htm.xml (XML) — 4KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On May 29, 2024, Larimar Therapeutics, Inc. (the " Company ") held its 2024 Annual Meeting of Stockholders (the " Annual Meeting ") virtually. As of April 1, 2024, the record date for the Annual Meeting, there were 63,800,017 outstanding shares of the Company's common stock, par value $0.001 per share, entitled to vote at the Annual Meeting. The following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the Annual Meeting, which are described in detail in the Company's definitive proxy statement for the Annual Meeting, filed with the U.S. Securities and Exchange Commission on April 29, 2024. Proposal 1 – Election of Class I Directors. Jonathan Leff and Jeffrey W. Sherman, M.D., FACP were elected to the Board of Directors of the Company as Class I directors to serve until the Company's 2027 Annual Meeting of Stockholders and until their successors, if any, are duly elected and qualified or appointed, or their earlier death, resignation, or removal, as follows: Name Votes For Votes Withheld Broker Non-Votes Jonathan Leff 40,728,411 10,501,069 8,332,013 Jeffrey W. Sherman, M.D., FACP 51,056,220 173,260 8,332,013 Proposal 2 – Approval, on an advisory basis, of the compensation of the Company's named executive officers in 2023. The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers in 2023, as follows: Votes For Votes Against Abstentions Broker Non-Votes 48,754,088 2,352,496 122,896 8,332,013 Proposal 3 – Ratification of Independent Registered Public Accountant. The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the 2024 fiscal year was ratified, as follows: Votes For Votes Against Abstentions Broker Non-Votes 59,557,743 2,735 1,015 0 Proposal 4 – Approval of an

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Larimar Therapeutics, Inc. Date: May 31, 2024 By: /s/ Carole S. Ben-Maimon, M.D. Name: Carole S. Ben-Maimon, M.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR